Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)

Trial Profile

Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Iloperidone (Primary) ; Olanzapine; Risperidone
  • Indications Mood disorders; Schizophrenia and disorders with psychotic features
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2014 The study protocol is amended to replace indication Schizophrenia with serious mental illness,including schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
    • 27 Mar 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015, as per ClinicalTrials.gov record.
    • 17 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top